Bio-Techne Corporation (TECH)

74,80 +11,59 (+18,34%) In data: 03:01PM EDT. Mercato aperto.

Bio-Techne Corporation

614 McKinley Place N.E.
Minneapolis, MN 55413
United States
612 379 8854
https://www.bio-techne.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 3.200

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Kim Kelderman	CEO, President & Director	845,71k	126,84k	1968
Mr. James T. Hippel	Executive VP of Finance & CFO	691,78k	N/D	1971
Mr. Shane Bohnen	Senior VP, General Counsel & Corporate Secretary	353,6k	N/D	1975
Mr. Charles R. Kummeth	Senior Advisor	1,26M	48,58M	1960
Mr. William A. Geist	President of Protein Sciences Segment	533,67k	N/D	1970
Dr. Gary J. Latham Ph.D.	VP & CTO	N/D	N/D	N/D
David Clair	Senior Director of Investor Relations & Corporate Development	N/D	N/D	N/D
Mr. Gerry Andros	Vice President of Sales and Marketing	N/D	N/D	N/D
Mr. Robert M. Gavin	Vice President of Corporate Development	724,51k	N/D	1968

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Governance aziendale

L'ISS Governance QualityScore di Bio-Techne Corporation al 29 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 5; diritti degli azionisti: 1; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.